N-(9-methylcarbazol-3-yl)-2,2-dimethylpropionamide | 373367-61-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: N-(9-methylcarbazol-3-yl)-2,2-dimethylpropionamide
• 英文别名: 2,2-dimethyl-N-(9-methylcarbazol-3-yl)propanamide
• CAS: 373367-61-4
• 化学式: C₁₈H₂₀N₂O
• 分子量: 280.37
• InChiKey: HQAFOXXAAJYYGK-UHFFFAOYSA-N

物化性质

• 沸点：
  449.6±27.0 °C(Predicted)
• 密度：
  1.11±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  34
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N,N-二甲基甲酰胺 、 N-(9-methylcarbazol-3-yl)-2,2-dimethylpropionamide 在 正丁基锂 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 3.0h， 生成 N-(2-formyl-9-methylcarbazol-3-yl)-2,2-dimethylpropionamide 、 N-(4-formyl-9-methylcarbazol-3-yl)-2,2-dimethylpropionamide
  参考文献：
  名称：

  摘要：

  2-, 3- and 4-Pivaloylamino derivatives of dibenzofuran [compounds (5), (4) and (6), respectively] and analogous 3-, 2- and 1-substituted derivatives of 9-methylcarbazole [compounds (8), (7) and (9), respectively] were subjected to lithiation at 0 degreesC and subsequent reaction with dimethylformamide. Aldehyde formation took place at positions alpha to delta to the heteroatom as follows: alpha for (4) and (7); delta for (5); delta and beta (3 : 1) for (8); and alpha' for (6). No formylation occurred with (9).

  DOI：

  10.1071/ch01017
• 作为产物：
  描述：

  咔唑 在 palladium on activated charcoal 硝酸 、 一水合肼 、 三乙胺 作用下， 以 乙醇 、 二氯甲烷 、 溶剂黄146 为溶剂， 反应 20.0h， 生成 N-(9-methylcarbazol-3-yl)-2,2-dimethylpropionamide
  参考文献：
  名称：

  摘要：

  2-, 3- and 4-Pivaloylamino derivatives of dibenzofuran [compounds (5), (4) and (6), respectively] and analogous 3-, 2- and 1-substituted derivatives of 9-methylcarbazole [compounds (8), (7) and (9), respectively] were subjected to lithiation at 0 degreesC and subsequent reaction with dimethylformamide. Aldehyde formation took place at positions alpha to delta to the heteroatom as follows: alpha for (4) and (7); delta for (5); delta and beta (3 : 1) for (8); and alpha' for (6). No formylation occurred with (9).

  DOI：

  10.1071/ch01017

文献信息

• Carbazole derivatives for the treatment of NPY related diseases
  申请人：Boehringer Ingelheim International GmbH

  公开号：US20040147752A1

  公开（公告）日：2004-07-29

  The invention relates to novel carbazole derivatives, their use for the preparation of a pharmaceutical composition for the treatment of eating and metabolic disorders such as obesity, bulimia nervosa, anorexia nervosa, of sleep disturbance, of morphine withdrawal symptoms and of epileptic seizures, a pharmaceutical composition containing them and a process for preparing them.

  本发明涉及新型咔唑衍生物，它们用于制备治疗饮食和代谢紊乱（如肥胖症、神经性贪食症、神经性厌食症）、睡眠障碍、吗啡戒断症状和癫痫发作的药物组合物，以及含有它们的药物组合物和制备它们的工艺。
• CARBAZOLE DERIVATIVES AND THEIR USE FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF NPY RELATED DISEASES
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP1395578A1

  公开（公告）日：2004-03-10
• [EN] CARBAZOLE DERIVATIVES AND THEIR USE FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF NPY RELATED DISEASES<br/>[FR] DERIVES DE CARBAZOLE ET LEUR UTILISATION POUR LA PREPARATION DE COMPOSITIONS PHARMACEUTIQUES DESTINEES AU TRAITEMENT DE MALADIES LIEES AU NEUROPEPTIDE Y (NPY)
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2002096902A1

  公开（公告）日：2002-12-05

  The invention relates to novel carbazole derivatives, their use for the preparation of a pharmaceutical composition for the treatment of eating and metabolic disorders such as obesity, bulimia nervosa, anorexia nervosa, of sleep disturbance, of morphine withdrawal symptoms and of epileptic seizures, a pharmaceutical composition containing them and a process for preparing them.
• [EN] HEPATITIS C VIRUS ENTRY INHIBITORS<br/>[FR] INHIBITEURS DE LA PÉNÉTRATION DU VIRUS DE L'HÉPATITE C
  申请人：IMMUSOL INC

  公开号：WO2008021745A2

  公开（公告）日：2008-02-21

  [EN] The present invention relates to the use of tricyclic diphenylamine derivative compounds for prevention and/or treatment of Hepatitis C virus (HCV) infection by inhibiting HCV entry into permissive cells.
  [FR] La présente invention concerne l'utilisation de composés dérivés de la diphénylamine tricyclique pour la prévention et/ou le traitement d'une infection par le virus de l'hépatite C (Hepatitis C Virus : HCV) en inhibant la pénétration du HCV dans les cellules permissives.